QRFT0.960%
as of Jul 8
ABBV
GrowthABBVIE INC.
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer.
Close · 3M
+11.40%
Held by 3 AI ETFs
Signal performance
Each tracked ETF's moves on this stock, grouped by fund. Returns are measured from the signal date to the latest close — hypothetical, no commissions or slippage.
Buy signals22
Win rate82% (18/22)
Avg buy return+9.63%
QRFT · Weight increase · 2d
The QRFT fund has recently applied a series of frequent, incremental weight adjustments to ABBV, moving its allocation from 0.9000% to 0.9900% over a roughly ten-day period with minor intraday fluctuations. This cadence of dynamic, fine-tuned rebalancing aligns directly with Qraft AI's methodology of combining traditional factors with proprietary alternative data overlays, designed for weekly portfolio adjustments across its broad large-cap core. Despite ABBV trading at 100% of its 52-week high and delivering a 30-day return of +23.0%, the AI's continued accumulation suggests strong positive signals from its momentum and quality factor overlays. Such elevated price performance is complemented by ABBV's financial metrics, including a 9.5% revenue growth and 95.59% ROE, which align with a "quality" tilt. The stock's high PER of 122.03 and PBR of 94.44 indicate the AI's algorithm is prioritizing current growth trajectories and price strength in the Health Care sector over traditional value considerations.
weight 0.940% → 0.990% (+0.050 pp)·stock up 21.2% in the 30 days before
Jul 2·entry $261.07·now $253.38Fresh
-2.95%
since Jul 2
QRFT · Weight decrease · 2d
ABBV currently trades at $251.64, positioned at 99% of its 52-week high of $254.31, following a significant 20.2% return over the past 30 days and 35.7% over one year. This rapid ascent and near-peak valuation, with a PER of 114.11 and PBR of 94.44, likely triggered a re-evaluation by Qraft AI's methodology, which considers traditional factors like value, momentum, quality, and low-volatility. While the company’s 9.5% revenue growth and 95.59% ROE demonstrate underlying quality, the AI's value and potential low-volatility components likely flagged the stock as increasingly overbought or overvalued given its current price trajectory and the market’s weekly rebalancing. Consequently, QRFT's AI initiated a consecutive weight decrease for ABBV on June 29th and 30th, reducing exposure from 0.97% to 0.94% as the stock approached its annual price ceiling.
weight 0.970% → 0.940% (-0.030 pp)·stock up 15.6% in the 30 days before
Jun 30·entry $251.64·now $253.38
+0.69%
since Jun 30
QRFT · Weight increase · 2d
The recent weight adjustments for ABBV in QRFT reveal a sustained accumulation, increasing from 0.81% to 0.97% over five trading days with mostly daily increments. This methodical elevation in allocation for ABBV, occurring as the stock reached its 52-week high and posted a 20.2% 30-day return, suggests Qraft AI’s system identified a reinforcing positive trend. The AI, combining traditional factors with proprietary alternative data, appears to have detected strengthening signals supporting continued exposure to this large-cap momentum, even as it touches the upper boundary of its 52-week range. The allocation choice, even with ABBV's current PER of 114.11 and PBR of 94.44, is likely driven by the company's 95.59% ROE and 9.5% revenue growth, which the AI deemed compelling within its diversified large-cap core framework.
weight 0.900% → 0.970% (+0.070 pp)·stock up 17.6% in the 30 days before
Jun 26·entry $253.35·now $253.38Fresh
+0.01%
since Jun 26
QRFT · Weight increase · 2d
The Qraft AI engine, governing QRFT's weekly rebalance for its approximately 300 US large-cap holdings, drove the consecutive weight increase in ABBV by processing a combination of traditional and proprietary alternative data. This broad large-cap core fund likely prioritized specific factors inherent in ABBV's current profile. For example, the stock's 95.59% Return on Equity presents a strong quality signal, while its 30-day return of +15.8% indicates significant recent momentum. Such attributes, filtered through Qraft's algorithms, prompted the AI to incrementally add to its position, even as ABBV approaches its 52-week high at $234.76.
weight 0.810% → 0.900% (+0.090 pp)·stock up 9.4% in the 30 days before
Jun 23·entry $234.76·now $253.38Drifting
+7.93%
since Jun 23
QRFT · Accumulation · 5d
Qraft Technologies' AI, which synthesizes traditional factors and proprietary alternative-data overlays, directed a gradual accumulation of ABBV shares within its portfolio of approximately 300 US large caps. This steady increase, visible in the shifts from 0.8100% to 0.8700% across the reported period, aligns with the fund's weekly rebalancing cadence as the AI continuously optimizes positions. The system likely registered positive signals from ABBV's 95.59% Return on Equity, a key indicator for quality and efficiency that the AI integrates. Additionally, the stock's 30-day return of +10.2% suggested strengthening momentum, a factor the AI considers alongside value, quality, and low volatility within its broad large-cap core approach.
weight 0.810% → 0.870% (+0.060 pp)·stock up 9.2% in the 30 days before
Jun 12·entry $227.73·now $253.38Chased
+11.26%
since Jun 12
QRFT · Accumulation · 5d
The observed gradual accumulation of ABBV, characterized by daily adjustments within a narrow range from 0.80% to 0.86% of QRFT's portfolio, reflects Qraft AI's methodology of weekly rebalancing and its broad large-cap core style. This measured increase in a company like ABBV, currently trading at $227.73 near its 52-week high, suggests the AI system is responding to strong signals from its momentum and quality factors, given the stock's 30-day return of +10.2% and its high ROE of 95.59%. Despite ABBV's elevated PER of 109.34 and PBR of 94.44, QRFT's AI, which integrates traditional factors with proprietary alternative-data overlays, likely weighs the sustained revenue growth of 9.5% heavily, while minor daily reductions in weight may indicate dynamic management informed by its low-vol component.
weight 0.800% → 0.860% (+0.060 pp)·stock up 8.1% in the 30 days before
Jun 11·entry $224.77·now $253.38Chased
+12.73%
since Jun 11
QRFT · Accumulation · 6d
The QRFT AI system engaged in a measured accumulation of ABBV, gradually increasing its portfolio weight from 0.77% to 0.88% over ten days, with a slight adjustment on June 8th. This deliberate daily cadence, consistent with QRFT's weekly rebalancing for its ~300 large-cap holdings, indicates the Qraft AI is likely responding to ABBV's strong 9.5% revenue growth and 95.59% ROE, alongside its recent +10.3% 30-day price momentum. Even with ABBV trading near its 52-week high and exhibiting a PER of 109.34, the fund’s blended factor approach, incorporating proprietary alternative-data overlays, seems to prioritize these quality and short-term momentum signals. This specific pattern suggests the AI’s core strategy, while diversified, identifies ABBV as a current fit across multiple criteria, overriding traditional valuation metrics for controlled exposure.
weight 0.770% → 0.880% (+0.110 pp)·stock up 10.9% in the 30 days before
Jun 10·entry $224.95·now $253.38Chased
+12.64%
since Jun 10
QRFT · Accumulation · 5d
QRFT's AI engine is exhibiting a pattern of gradual accumulation in ABBV, consistently increasing its weight over several trading days with small adjustments, even after a minor reduction on June 8th before resuming the upward trend. This deliberate, incremental approach makes sense for a fund rebalancing weekly, particularly when addressing a stock currently trading near its 52-week high at $225.42 and showing a 14.0% 30-day return, yet also possessing a high ROE of 95.59% and 9.5% revenue growth. The AI's integration of traditional factors like momentum alongside proprietary alternative data likely identified reinforcing signals for ABBV, prompting calculated increases to its position while potentially navigating the company’s PER of 104.7 and PBR of 94.44. Such a nuanced strategy allows this broad large-cap core fund to capture upside from ongoing positive trends without making abrupt, large commitments.
weight 0.790% → 0.870% (+0.080 pp)·stock up 11.8% in the 30 days before
Jun 9·entry $225.42·now $253.38Chased
+12.40%
since Jun 9
+11.51%
since Jun 5
+12.64%
since Jun 4
+16.70%
since Jun 3
QRFT · Weight increase · 2d
stock up 10.6% in the 30 days before
May 28·entry $218.63·now $253.38Chased
+15.89%
since May 28
PQUS · Weight increase · 2d
ABBV's significant return on equity of 95.59% and 9.5% revenue growth likely signal strong fundamental quality to Pictet Asset Management's AI ranking system for PQUS, despite its high PER of 123.69 and PBR of 94.44. The consecutive weight increase in PQUS, observed from 0.63% to 0.67% between July 17th and July 19th, 2026, occurred as ABBV traded near 97% of its 52-week high, having delivered a 30-day return of +13.1%. The AI system for PQUS, managing its US large-cap portfolio with measured turnover, evidently confirmed ABBV's favorable standing, adding exposure even as the stock neared its 52-week peak after a substantial 30-day gain.
weight 0.630% → 0.670% (+0.040 pp)·stock up 14.4% in the 30 days before
Jul 19·entry $253.38·now $253.38Fresh
0.00%
since Jul 19
PQUS · Weight decrease · 2d
The weight of ABBV within the PQUS portfolio exhibits a subtle, generally decreasing pattern, drifting from 0.67% down to 0.63% over the period, interspersed with brief stable periods. This gradual de-weighting by Pictet Asset Management’s AI system likely reflects a reaction to ABBV’s considerable price momentum, which has placed the stock at 97% of its 52-week high following a 17.2% return in just 30 days. As a fund balancing ~165 US large-cap holdings, PQUS employs sector-balance and concentration rules, making such rapid appreciation a potential trigger for the AI to manage exposure without daily rebalances. The adjustments align with its measured turnover style, carefully reducing the position in a company trading at a PER of 121.47 and a PBR of 94.44, notwithstanding its 95.59% ROE.
weight 0.650% → 0.630% (-0.020 pp)·stock up 14.4% in the 30 days before
Jul 17·entry $254.49·now $253.38
-0.44%
since Jul 17
PQUS · Weight decrease · 2d
ABBV's Price-to-Earnings ratio of 121.47 and Price-to-Book ratio of 94.44, combined with a 95.59% Return on Equity, likely informed Pictet Asset Management's AI ranking system for PQUS, an ETF designed for US large-cap exposure with measured turnover. This valuation, particularly as the stock traded at 95% of its 52-week high of $261.07 following a 30-day return of +13.5%, prompted the system to initiate a rebalance. Consequently, the fund experienced a consecutive weight decrease in ABBV from 0.6900% to 0.6400% between July 8th and July 12th, 2026, aligning with PQUS's periodic rebalancing approach for its approximately 165 US large-cap holdings.
weight 0.670% → 0.640% (-0.030 pp)·stock up 10.1% in the 30 days before
Jul 12·entry $248.00·now $253.38
+2.17%
since Jul 12
PQUS · Weight increase · 2d
ABBV is currently priced at $253.35, sitting precisely at 100% of its 52-week high, having delivered a +20.2% return over the last 30 days and +32.6% over the past year. Observing this strong price momentum, combined with financial indicators like 9.5% revenue growth and a 95.59% ROE, Pictet's AI ranking system for PQUS increased its weight in ABBV from 0.82% to 0.91% between June 23 and June 25. Subsequently, on June 26, the fund's weight was reduced to 0.64%, suggesting the AI system, within its periodic rebalancing cycle, applied sector-balance or concentration rules or responded to the stock’s elevated PER of 114.11 after hitting its 52-week high. This movement reflects the fund's strategy of initial capital deployment into an ascending large-cap stock, followed by an adjustment once specific portfolio constraints or valuation triggers are met.
weight 0.640% → 0.690% (+0.050 pp)·stock up 17.6% in the 30 days before
Jun 28·entry $254.31·now $253.38Fresh
-0.37%
since Jun 28
PQUS · Weight increase · 2d
The Pictet Asset Management AI ranking system, governing PQUS's ~165 US large-cap holdings with periodic rebalancing, appears to have reallocated capital towards ABBV. This decision to increase the health care stock's weight consecutively to 0.91% from 0.82% indicates that the AI's criteria for selection were met during its latest review cycle. The system likely recognized the company's strong operational performance, evidenced by its 95.59% Return on Equity. Furthermore, ABBV's 13.0% return over the last 30 days, while trading at 96% of its 52-week high, aligns with the ETF's measured turnover style, signaling positive momentum without a dramatic shift in portfolio concentration.
weight 0.820% → 0.910% (+0.090 pp)·stock up 14.1% in the 30 days before
Jun 25·entry $243.14·now $253.38Drifting
+4.21%
since Jun 25
PQUS · Weight increase · 2d
ABBV, currently priced at $216.49, sits at 89% of its 52-week high, experiencing a 6.8% gain over the past 30 days which followed a 2.7% decline over 90 days. This recent positive price action, occurring within a periodic rebalance cycle for the newer PQUS fund, appears to have influenced Pictet Asset Management's AI ranking system. The AI, which manages a US large-cap universe with sector-balance and concentration rules, incrementally adjusted ABBV's weight from 0.81% on June 17 to 0.85% by June 19. This sequential increase in allocation for the Health Care company suggests the AI's assessment weighted ABBV's 95.59% ROE and 9.5% revenue growth, despite its PER of 105.22 and PBR of 94.44.
weight 0.810% → 0.850% (+0.040 pp)·stock up 1.3% in the 30 days before
Jun 19·entry $230.01·now $253.38Chased
+10.16%
since Jun 19
PQUS · Weight decrease · 2d
ABBV exhibits a high PER of 109.34 and a PBR of 94.44, alongside a 95.59% ROE and 9.5% revenue growth. For the Pictet Asset Management's PQUS ETF, an AI ranking system evaluating US large caps would consider these valuation multiples in conjunction with its operational efficiency. The weight adjustments in PQUS for ABBV, specifically the consecutive decrease from 1.04% to 0.84% on June 12 and 13, occurred as the stock traded at 93% of its 52-week high, following a 10.2% gain over 30 days. This pattern suggests the AI’s re-evaluation of ABBV’s positioning within the large-cap universe, possibly influenced by the rapid price appreciation against its valuation metrics. The measured turnover style of this newer fund allows for such periodic rebalancing, reflecting the AI's system reacting to a stock approaching a higher end of its recent price range while maintaining sector balance.
weight 1.040% → 0.840% (-0.200 pp)·stock up 9.2% in the 30 days before
Jun 13·entry $221.59·now $253.38
+14.35%
since Jun 13
PQUS · Weight increase · 2d
stock up 10.8% in the 30 days before
Jun 7·entry $223.07·now $253.38Chased
+13.59%
since Jun 7
+12.64%
since Jun 4
+16.38%
since May 29
AIEQ · Weight decrease · 2d
Utilizing IBM Watson NLP to continuously analyze news, filings, and social posts across thousands of US equities, AIEQ's system, which daily rebalances its 140-180 stock portfolio, executed a rapid reduction in its ABBV holding. This decisive move, slashing ABBV's weight from 1.17% to 0.05% within a single day, indicates that the fund's broad market, fundamentals + sentiment hybrid style identified a deteriorating outlook. Despite a 9.5% revenue growth, the AI's output feeding EquBot's risk overlay likely flagged concerns such as the stock’s current position at 99% of its 52-week high or its high PER of 122.03, prompting the swift de-risking.
weight 1.180% → 0.050% (-1.130 pp)·stock up 17.9% in the 30 days before
Jul 1·entry $251.06·now $253.38
+0.92%
since Jul 1
AIEQ · Weight increase · 2d
ABBV's AIEQ weight initially dipped, then saw a distinct stepped increase from 0.99% to 1.09% on June 24, followed by a sustained daily accumulation to 1.18% by June 28. This pattern suggests Amplify ETFs' daily rebalancing, driven by IBM Watson's NLP, detected a significant positive shift in sentiment or fundamental indicators around June 24. Despite ABBV trading at 100% of its 52-week high after a 30-day return of +20.2%, the fund’s hybrid strategy likely found justification in the company's 95.59% ROE and 9.5% revenue growth. The EquBot risk overlay appears to be consistently validating and acting on a sustained positive ranking for ABBV, reflecting a continuous feed of favorable news or analyses processed by the system.
weight 1.090% → 1.180% (+0.090 pp)·stock up 17.6% in the 30 days before
Jun 28·entry $254.31·now $253.38Fresh
-0.37%
since Jun 28
AIEQ · Weight increase · 2d
Currently trading at $216.49, ABBV stands at 89% of its 52-week high, following a recent 30-day return of +6.8% which contrasts with its negative 90-day trajectory. This setup indicates a recent shift in sentiment that IBM Watson's NLP engine, which feeds into AIEQ's daily position adjustments, likely detected, especially given ABBV's 9.5% revenue growth and 95.59% ROE, despite a high PER of 105.22. The fund, known for its frequent turnover, then registered a consecutive weight increase for ABBV, reaching 1.02% on June 18th from 1.01% the prior day, following an earlier drop to 1.00% on June 16th. This precise move suggests the EquBot risk overlay translated emerging positive signals from news, filings, and social posts into a slightly higher allocation, despite the stock being near its annual peak.
weight 1.000% → 1.020% (+0.020 pp)·stock up 1.3% in the 30 days before
Jun 18·entry $216.49·now $253.38Chased
+17.04%
since Jun 18
AIEQ · Accumulation · 5d
ABBVIE INC.'s financial summary, showing a PER of 109.34, PBR of 94.44, and a ROE of 95.59%, highlights a company with significant valuation and profitability, fitting AIEQ's broad market, fundamentals + sentiment hybrid investment style. The gradual accumulation of ABBV by AIEQ between June 3rd and June 11th, increasing its weight from 0.9700% to 1.0600%, occurred as the stock traded at $224.77, reflecting a +6.4% 30-day return and positioning it at 92% of its 52-week high after a negative 90-day performance. This consistent buying action by Amplify ETFs' AIEQ, which relies on IBM Watson NLP to process vast data daily for rankings, suggests continuous positive signals in ABBV's news, filings, or social posts, even as the stock price ascended. The fund’s high-turnover, daily rebalancing mechanism enabled this precise, incremental adjustment in response to the observed financial and sentiment data for ABBV.
weight 0.970% → 1.060% (+0.090 pp)·stock up 8.1% in the 30 days before
Jun 11·entry $224.77·now $253.38Chased
+12.73%
since Jun 11
AIEQ · Weight increase · 3d
stock up 10.8% in the 30 days before
Jun 7·entry $223.07·now $253.38Chased
+13.59%
since Jun 7
AIEQ · Weight increase · 2d
stock up 10.8% in the 30 days before
Jun 5·entry $227.23·now $253.38Chased
+11.51%
since Jun 5
+19.00%
since May 30
Sell signals show what the stock did after the AI exited. A negative number means the AI's exit was well-timed.
Buffett-style framework
Too hard to callas of Jul 12
The AI ETFs show mixed signals, with AIEQ and PQUS generally decreasing their weight in ABBV, while QRFT exhibits some recent increases and decreases. This somewhat aligns with the 'Too Hard' verdict, suggesting a cautious or uncertain stance, rather than a strong conviction buy or sell.
- Circle of CompetenceThe pharmaceutical industry's reliance on patent-protected drugs and the inherent uncertainty of R&D success make long-term cash flow projections genuinely unpredictable beyond a few years for a generalist investor.
- Economic MoatWhile specific drugs enjoy patent protection creating a temporary moat, the company's long-term competitive advantage depends heavily on continuous, unpredictable R&D success and strategic acquisitions to replace expiring patents.
- ManagementThe provided data is insufficient to adequately assess management's candor, capital allocation discipline, or skin in the game.
- Financial HealthKey financial health indicators, such as 10-year average ROE, a comprehensive debt profile, and consistent owner earnings, cannot be fully assessed with the limited data provided.
- Margin of SafetyWithout reliable long-term cash flow projections and a conservative estimate of intrinsic value, it is impossible to determine if a defensible margin of safety exists at the current price.
AbbVie operates in an industry where projecting ten-year cash flows is inherently challenging for a generalist investor due to the unpredictable nature of R&D and the impact of patent expirations, placing it outside the typical circle of competence for this framework. Consequently, assessing its economic moat, management, financial health, and margin of safety becomes speculative without first establishing reliable earning power predictability. The framework therefore declines to score the company further.
Educational interpretation generated by AI applying frameworks Warren Buffett documented in his shareholder letters and other public writings. Not a statement by Mr. Buffett or Berkshire Hathaway, and not investment advice.